Rankings
▼
Calendar
CCCC Q3 2024 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CCCC
C4 Therapeutics, Inc.
$243M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$15M
+38.7% YoY
Gross Profit
$13M
86.6% margin
Operating Income
-$28M
-183.9% margin
Net Income
-$25M
-160.6% margin
EPS (Diluted)
$-0.35
QoQ Revenue Growth
+28.0%
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$24M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$376M
Total Liabilities
$133M
Stockholders' Equity
$243M
Cash & Equivalents
$60M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$15M
$11M
+38.7%
Gross Profit
$13M
$9M
+46.6%
Operating Income
-$28M
-$28M
-1.6%
Net Income
-$25M
-$27M
+8.8%
← FY 2024
All Quarters
Q4 2024 →